Literature DB >> 19138938

Colorectal neoplasia goes with the flow: prostaglandin transport and termination.

Sanford D Markowitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19138938      PMCID： PMC2533154          DOI： 10.1158/1940-6207.CAPR-08-0009

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN： 1940-6215


× No keyword cloud information.
  31 in total

Review 1.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise.

Authors:  Andrew J Dannenberg; Kotha Subbaramaiah
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743

2.  Celecoxib for the prevention of sporadic colorectal adenomas.

Authors:  Monica M Bertagnolli; Craig J Eagle; Ann G Zauber; Mark Redston; Scott D Solomon; KyungMann Kim; Jie Tang; Rebecca B Rosenstein; Janet Wittes; Donald Corle; Timothy M Hess; G Mabel Woloj; Frédéric Boisserie; William F Anderson; Jaye L Viner; Donya Bagheri; John Burn; Daniel C Chung; Thomas Dewar; T Raymond Foley; Neville Hoffman; Finlay Macrae; Ronald E Pruitt; John R Saltzman; Bruce Salzberg; Thomas Sylwestrowicz; Gary B Gordon; Ernest T Hawk
Journal:  N Engl J Med       Date:  2006-08-31       Impact factor: 91.245

3.  Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR.

Authors:  Nathalie Maubon; Marc Le Vee; Lina Fossati; Mathilde Audry; Eric Le Ferrec; Sebastien Bolze; Olivier Fardel
Journal:  Fundam Clin Pharmacol       Date:  2007-12       Impact factor: 2.748

4.  Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.

Authors:  Scott D Solomon; John J V McMurray; Marc A Pfeffer; Janet Wittes; Robert Fowler; Peter Finn; William F Anderson; Ann Zauber; Ernest Hawk; Monica Bertagnolli
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer.

Authors:  Ido Wolf; James O'Kelly; Tamar Rubinek; Min Tong; Anh Nguyen; Bryan T Lin; Hsin-Hsiung Tai; Beth Y Karlan; H Phillip Koeffler
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

6.  Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha.

Authors:  Taisuke Otani; Kentaro Yamaguchi; Ellen Scherl; Baoheng Du; Hsin-Hsiung Tai; Melanie Greifer; Lydia Petrovic; Takiko Daikoku; Sudhansu K Dey; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-09-29       Impact factor: 4.052

7.  The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.

Authors:  Linda C Hsi; Xiaopei Xi; Reuben Lotan; Imad Shureiqi; Scott M Lippman
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

8.  Disruption of cAMP and prostaglandin E2 transport by multidrug resistance protein 4 deficiency alters cAMP-mediated signaling and nociceptive response.

Authors:  Z Ping Lin; Yong-Lian Zhu; Dennis R Johnson; Kevin P Rice; Timothy Nottoli; Bryan C Hains; James McGrath; Stephen G Waxman; Alan C Sartorelli
Journal:  Mol Pharmacol       Date:  2007-10-24       Impact factor: 4.436

9.  Regulation of prostaglandin transporters in colorectal neoplasia.

Authors:  Vijaykumar R Holla; Michael G Backlund; Peying Yang; Robert A Newman; Raymond N DuBois
Journal:  Cancer Prev Res (Phila)       Date:  2008-03-19

10.  Cyclooxygenase regulates angiogenesis induced by colon cancer cells.

Authors:  M Tsujii; S Kawano; S Tsuji; H Sawaoka; M Hori; R N DuBois
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582
View more
  5 in total

1.  PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Wolfram Goessling; Andrew T Chan; Kimmie Ng; Jennifer A Chan; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

2.  Large-Scale Genome-Wide Association Study of East Asians Identifies Loci Associated With Risk for Colorectal Cancer.

Authors:  Yingchang Lu; Sun-Seog Kweon; Chizu Tanikawa; Wei-Hua Jia; Yong-Bing Xiang; Qiuyin Cai; Chenjie Zeng; Stephanie L Schmit; Aesun Shin; Keitaro Matsuo; Sun Ha Jee; Dong-Hyun Kim; Jeongseon Kim; Wanqing Wen; Jiajun Shi; Xingyi Guo; Bingshan Li; Nan Wang; Ben Zhang; Xinxiang Li; Min-Ho Shin; Hong-Lan Li; Zefang Ren; Jae Hwan Oh; Isao Oze; Yoon-Ok Ahn; Keum Ji Jung; David V Conti; Fredrick R Schumacher; Gad Rennert; Mark A Jenkins; Peter T Campbell; Michael Hoffmeister; Graham Casey; Stephen B Gruber; Jing Gao; Yu-Tang Gao; Zhi-Zhong Pan; Yoichiro Kamatani; Yi-Xin Zeng; Xiao-Ou Shu; Jirong Long; Koichi Matsuda; Wei Zheng
Journal:  Gastroenterology       Date:  2018-12-06       Impact factor: 22.682

3.  Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.

Authors:  Stephen P Fink; Dawn M Dawson; Yongyou Zhang; Adam Kresak; Earl G Lawrence; Peiying Yang; Yanwen Chen; Jill S Barnholtz-Sloan; Joseph E Willis; Levy Kopelovich; Sanford D Markowitz
Journal:  Carcinogenesis       Date:  2014-12-10       Impact factor: 4.944

4.  Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance.

Authors:  Kishore Guda; Stephen P Fink; Ginger L Milne; Neil Molyneaux; Lakshmeswari Ravi; Susan M Lewis; Andrew J Dannenberg; Courtney G Montgomery; Shulin Zhang; Joseph Willis; Georgia L Wiesner; Sanford D Markowitz
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-16

5.  The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation.

Authors:  Qianqian Pang; Yuping Xu; Xuan Qi; Yan Jiang; Ou Wang; Mei Li; Xiaoping Xing; Ling Qin; Weibo Xia
Journal:  Endocr Connect       Date:  2019-06       Impact factor: 3.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.